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Abstract 
BRAF inhibitors may present several cutaneous adverse effects, including actinic keratosis, 
squamous cell carcinoma, keratoacanthoma, rashes, increased photosensitivity, panniculitis, 
palmoplantar and capillary involvement, pruritus and xerosis as well as granulomatous reac-
tions. A 30-year-old patient with multiple tattoos received dabrafenib and trametinib for met-
astatic melanoma. After 4 months, he developed an induration and thickening strictly limited 
to several tattoos. Histopathology revealed nonnecrotizing granulomas in the dermis. Topical 
steroids relieved pruritus but not the granulomatous aspect of the tattoos. As far as we know, 
this is the first description of granulomatous reactions restricted to preexisting tattoos follow-
ing BRAF inhibitor therapy. © 2019 The Author(s) 
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BRAF mutations are found in 40–60% of melanomas [1, 2]. BRAF inhibitors like dabraf-
enib are routinely used in the treatment of advanced melanoma [3].  
The combination of BRAF inhibitors with MEK inhibitors decreases the resistance to 
treatment and the adverse effects except pyrexia. In addition to pyrexia, the most common 
adverse effects are arthralgia, fatigue, and digestive disorders [1, 4]. Actinic keratosis, squa-
mous cell carcinoma, and keratoacanthoma, rashes with variable presentations, increased 
photosensitivity, panniculitis, palmoplantar and capillary involvement, pruritus and xerosis 
are among the most frequently reported skin side effects [1, 2]. Granulomatous reactions have 
been described in association with BRAF inhibitors [1–9] but, as far as we are aware of, no 
previous report exists on granulomatous reactions strictly limited to tattoos. 
Case Report  
A 30-year-old Caucasian patient, without any significant medical, allergologic or surgical 
history, presented initially with right neuralgia-like costal pain. After several months of mis-
diagnosis, a workup including angio-CT revealed a suspicious mediastinal mass of 5 × 8 cm 
behind the right bronchus, parenchymal pulmonary micronodules, and a thickening of the di-
aphragmatic cupola with pleural and pericardial reactions. A PET-CT discovered a second 
right paravertebral focus and several suspect lymph nodes. A thoracoscopic biopsy was per-
formed and a histopathological examination revealed the presence of a malignant tumor that 
did not express epithelial or lymphoid markers but expressed markers of soft and melanocyte 
tissues, including S100a, HMB45, NKIC3, and Melan-A. Furthermore, a BRAF v600e mutation 
was evidenced. The final diagnosis was metastatic melanoma. 
A thorough dermatological examination was performed but no primary lesion was found. 
The patient presented a high number of halo nevi, suggesting that the primary lesion could 
have regressed.  
The patient was a professional tattooist and his own cutaneous surface was extensively 
covered with different kinds of tattoos and colors. 
After 4 months of combined treatment with dabrafenib (BRAF inhibitor) and trametinib 
(MEK inhibitor), he progressively developed an asymptomatic thickening and induration of 
several of his tattoos. There were no other skin signs. Clinically, the tattoos presented a 3-
dimensional appearance (Fig. 1) and were slightly itchy. The histopathological analysis of a 
cutaneous punch biopsy revealed the presence of a histiocytic infiltrate grouped into small, 
nonnecrotizing, narrowly confluent granulomas associated with the presence of abundant 
black pigmentary deposits, both intra- and extracellularly, with an exogenous appearance 
(Fig. 2a–c). Strong potency topical corticosteroids were prescribed with a partial improve-
ment of the pruritus but no improvement of the infiltration of the tattoos. The main etiologies 
of pathologies leading to the formation of nonnecrotizing granulomas were excluded. Blood 
samples for ACE were negative.  
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Several cases of BRAF inhibitor-induced granulomatous cutaneous skin reactions have 
been reported in the literature. Table 1 summarizes the age and gender, the incriminated 
BRAF inhibitor, the time interval between the initiation of the BRAF inhibitor treatment and 
the cutaneous eruption and details the clinical aspects as well as the histological features of 
the reported cases. 
Seven cases were associated with dabrafenib and one with vemurafenib. The mean age of 
the patients is 59.5 years and the gender ratio is 6 females/3 males. The mean time interval 
from the start of the BRAF inhibitor therapy is 5.75 months (min: 1.75 months, max: 9 
months). All the cases presented lesions of the upper and/or lower extremities and only one 
case presented nodules on the trunk. The lesions were in general asymptomatic, tender to 
indurated, erythematous to brown papulo-nodules. The histological aspects were similar in 
all the reported cases, with nonnecrotizing granulomatous formations in the mid/deep der-
mis, composed of histiocytes, multinucleated giant cells and lymphocytes. In the majority of 
cases, an improvement could be observed under topical corticosteroids and anti-BRAF treat-
ment could be continued. The pathogenesis still remains unclear. 
This case presents granulomatous reactions restricted to the tattoos of the patient, ex-
plaining the granulomatous aspect. Probably, this phenomenon could respond to the Köbner 
effect, well known for granulomatous reactions [10]. On the other hand, granulomatous reac-
tions have been described in tattoos [11]. However, in our patient, it is highly probable that 
the granulomatous reactions are associated with the BRAF inhibitor treatment as the patient 
had already had numerous tattoos for years. Another hypothesis could be the development of 
a rush phenomenon affecting several tattoos simultaneously, associated with joint pains, iritis, 
erythema nodosum, lung sarcoidosis, and scar sarcoidosis. Indeed, black tattoos have a 500 
times increased risk of granuloma formation/sarcoidosis. Hence, in our patient the tattoo 
changes could also be attributed to a coincidental sarcoid development, triggered by the met-
astatic melanoma burden and/or the BRAF/MEK inhibitor therapy [12–14]. 
In conclusion, according to our knowledge, this is the first description of granulomatous 
reactions restricted to preexisting tattoos following BRAF inhibitor therapy.  
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Fig. 1. A grazing light incidence clearly reveals the granulomatous aspect of the tattoos of the patient. 
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Fig. 2. a Dense granulomatous infiltrate of the superficial and mid dermis. Note numerous tattoo pigments 
(H/E, ×20). b Well-delimited nonnecrotizing granulomas with tattoo pigments (H/E, ×100). c. Tattoo pig-
ments localized in both intra- and extracellular localizations of the nonnecrotizing granulomas. Some for-
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Table 1. Comparative table of BRAF inhibitor-induced granulomatous cutaneous skin reactions 
        
        







Clinical aspect  Histological features 
        
        
5 F 41 Dabrafenib 8 months Erythematous subcutaneous nodules in 
the upper and lower limbs 
Lobular panniculitis with lymphohistio-
cytic infiltrate organized into nonnecrotiz-
ing granulomas 
                6 F 59 Unspecified 1.75 months Painful livid subcutaneous nodules on 
the upper and lower extremities 
 Septolobular panniculitis with neutrophilic 
infiltrate and minor groups of other inflam-
matory cells included isolated noncaseat-
ing granulomas 
                1 F 80 Dabrafenib 2 months Erythematous/violaceous, firm, 1- to 2-
mm papules and an erythematous, in-
durated 5-cm plaque on the right leg, 
around the knee 
 First biopsy: granulomas with hybrid sar-
coidal and foreign body type features encir-
cling and edematous and degenerated fo-
cus of the reticular dermis. No melanoma 
cells identified 
Second biopsy: metastatic melanoma with 
a granulomatous response in the mid-retic-
ular dermis 
                1 M 70 Vemurafenib 5 months Multiple asymptomatic erythema-
tous/violaceous papules scattered over 
bilateral upper and lower extremities 
 Granulomas composed of histiocytes, Lang-
erhans-type multinucleated giant cells and 
lymphocytes in the reticular dermis with 
predilection to form around blood vessels 
                7 M 55 Dabrafenib 10 months Erythematous and slightly squamous 
round plaques on upper trunk and on 
left upper arm 
 Granulomatous dermatitis in the superfi-
cial reticular dermis. 
Admixed abundant melanophages from tu-
moral melanosis seen in one of the two 
skin biopsies. No melanoma cells seen in 
any of the specimens 
                8 M 72 Dabrafenib 7 months Nonpruritic, nontender, nonscaly, ery-
thematous papules and plaques on legs 
and arms 
 Interface dermatitis with increased dermal 
mucin deposition with foci of sarcoidal-
type granulomas 
                8 F 62 Dabrafenib 9 months A dark brown irregularly shaped mac-
ule on the right posterior shoulder 
 Junctional nevus with lentiginous architex-
tural disorder and mild cytological atypia, 
with focal underlying sarcoidal-type granu-
lomatous inflammation 
                9 F 50 Dabrafenib 2 months Multiple, erythematous, indurated, ten-
der subcutaneous nodules bilaterally 
on the anterior thighs, posterior arms 
and left dorsal forearm without overly-
ing epidermal change 
 Panniculitis with necrotizing granulomas 
        
        
 
 
 
